Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.58 |
| ▸ | FPR2 | P25090 | 2/20 | 0.38 |
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5439933 | 0.87 | F10 (0.46) | F10FPR2FPR1HDAC6HDAC1 | |
| SCHEMBL8266728 | 0.86 | F10 (0.53) | F10HDAC6ACHEROCK2 | |
| SCHEMBL14372326 | 0.86 | F10 (0.53) | F10HDAC6ACHEROCK2 | |
| SCHEMBL5184753 | 0.79 | F10 (0.53) | F10SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL8267036 | 0.79 | F10 (0.53) | F10SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL5433580 | 0.79 | F10 (0.47) | F10HDAC6HDAC8SLC6A2SLC6A4 | |
| SCHEMBL5431305 | 0.79 | F10 (0.47) | F10HDAC6HDAC8SLC6A2SLC6A4 | |
| SCHEMBL5185610 | 0.79 | F10 (0.42) | F10FPR2FPR1HDAC6HDAC1 | |
| SCHEMBL6359928 | 0.78 | TSHR (0.44) | F10FPR2FPR1HDAC6HDAC1 | |
| SCHEMBL8266599 | 0.76 | F10 (0.43) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249705-A1 | N-(1-(2,3-Dihydro-1H-Inden-5Yl)-2-Oxo-3-Pyrrolidinyl)-Sulfonamide Derivatives for Use as Factor Xa Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249705-A1 | N-(1-(2,3-Dihydro-1H-Inden-5Yl)-2-Oxo-3-Pyrrolidinyl)-Sulfonamide Derivatives for Use as Factor Xa Inhibitors | F11, F12, TFPI | F10 7/4885FPR2 596/4885FPR1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.